BRACE Home / Supporters
BRACE trial supporters
With the support of visionary philanthropists, the BRACE trial has become the largest study of its kind worldwide.
A special thank you to our generous donors
The face of BRACE?
BRACE is a randomised controlled trial that includes more than 6800 healthcare workers recruited in 36 sites across five countries to assess whether the off-target effects of Bacille Calmette-Guérin (BCG) vaccination reduce the incidence of symptomatic and severe COVID-19. The study is also investigating whether BCG vaccine reduces the impact of other illnesses, such as respiratory illnesses and allergic diseases.
In April 2021, the trial introduced the BRACE COVID-19-Specific vaccine sub-study (BCOS) to explore whether it’s possible to predict who remains susceptible to SARS-CoV-2 variants despite previous COVID-19 infection or COVID-19-specific vaccination. The sub-study will look at whether BCG vaccine improves the immune response to Pfizer, AstraZeneca and CoronaVac vaccines.
So far, the international study team of more than 350 researchers and staff have collected more than a quarter of a million samples, attracted a global media audience of more than five billion people and secured $15 million-plus in philanthropic funding – and all this with a 100-year old vaccine.